Lenalidomide-related diarrhea is associated with gut microbiota dysbiosis and disruption of the bile acid pool

K Kevin Miller (1Memorial Sloan Kettering Cancer Center, Myeloma Service, Department of Medicine, New York, United States) T Teng Fei (College of Life and Health Sciences, Northeastern University) R Ruben Ramos (2Memorial Sloan Kettering Cancer Center, New York, United States) A Ana Catarina Gradissimo De Oliveira (1Memorial Sloan Kettering Cancer Center, Pediatrics, New York, United States) J Jennifer Haber (1Memorial Sloan Kettering Cancer Center, Pediatrics, New York, United States) M Minsu Jaun (2Memorial Sloan Kettering Cancer Center, New York, United States) F Francesca Castro (1Memorial Sloan Kettering Cancer Center, Myeloma and Cellular Therapy Services, New York, United States) A Andriy Derkach I Issam Hamadeh (6Memorial Sloan Kettering Cancer Center, Department of Pharmacy, New York, United States) K Kylee Maclachlan (2Myeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY) M Malin Hultcrantz (1Memorial Sloan Kettering Cancer Center, Myeloma Service, Department of Medicine, New York, United States) H Hani Hassoun (1Memorial Sloan Kettering Cancer Center, Myeloma Service, Department of Medicine, New York, United States) S Sham Mailankody (Cellular Therapy Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York) S Sridevi Rajeeve (1Memorial Sloan Kettering Cancer Center, Myeloma Service, Department of Medicine, New York, United States) F Francesco Maura (Memorial Sloan Kettering Cancer Center, New York) M Maximillian Merz (5Memorial Sloan Kettering Cancer Center, New York, United States) H Hamza Hashmi (Memorial Sloan Kettering Cancer Center, New York) R Ross Firestone (1Memorial Sloan Kettering Cancer Center, Myeloma Service, Department of Medicine, New York, United States) E Eric Jurgens (1Memorial Sloan Kettering Cancer Center, Myeloma Service, Department of Medicine, New York, United States) G Gunjan Shah (2Memorial Sloan Kettering Cancer Center, Cellular Therapy Service, Department of Medicine, New York, United States) M Michael Scordo (Cellular Therapy Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York) H Heather Landau (Adult Bone Marrow Transplantation Service Memorial Sloan Kettering Cancer Center New York New York USA) J Jonathan Peled (1Memorial Sloan Kettering Cancer Center, Pediatrics, New York, United States) S Sergio Giralt (1Adult Bone Marrow Transplantation Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY) N Neha Korde (1Memorial Sloan Kettering Cancer Center, Myeloma Service, Department of Medicine, New York, United States) S Saad Usmani (8Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY) U Urvi Shah (1Memorial Sloan Kettering Cancer Center, Myeloma Service, Division of Hematologic Malignancies, Department of Medicine, New York, United States) A Alexander Lesokhin (1Memorial Sloan Kettering Cancer Center, Myeloma Service, Department of Medicine, New York, United States)

Abstract

Abstract Background Lenalidomide is a cornerstone of multiple myeloma (MM) treatment, but frequently causes gastrointestinal (GI) toxicity, which often manifests as diarrhea. Lenalidomide-related diarrhea (LRD) affects quality-of-life and therapeutic tolerance. A case series of 12 patients suggested bile acid (BA) malabsorption is present in LRD (PMID: 25301337). Symptom responsiveness to BA binders (colesevelam) has been described (PMID: 39300066), but the underlying mechanism of LRD is not known. Because microbial metabolism of BAs is integral to GI homeostasis, disruption of the gut microbiota and BA pool can exacerbate many GI diseases. We hypothesized gut microbiota disruption affects BA processing capacity and contributes to LRD. Methods Two prospective trials evaluating single-agent lenalidomide maintenance after front-line MM therapy were performed at our institution (NCT02538198, NCT04497961). Stool and PRO-CTCAE questionaries were collected pre-treatment (baseline) and on lenalidomide (on-len) at regular intervals. Patients submitted additional stool and PRO-CTCAE at diarrhea onset. Dietary food frequency questionaries were also collected. On-len stool samples were overlayed with PRO-CTCAE diarrhea responses and classified as on-len control (Never, Rarely) or on-len diarrhea (Occasionally, Frequently, Almost Constantly). Patients reporting diarrhea at baseline were excluded. 16S rRNA sequencing was performed on stool samples. Alpha-diversity (Simpson's reciprocal index) was modelled with a multivariable generalized estimating equation (GEE). Between-group microbial differences (beta-diversity) were defined by Bray-Curtis distance and assessed with PERMANOVA. FLORAL GEE models were used to select predictive microbial taxa. Stool BAs were quantified by LC-MS/MS and compared using linear mixed-effects models with Tukey-adjusted pairwise comparisons. PICRUSt2 was used to predict metagenomic functions. Dietary nutrient densities were compared with Wilcoxon rank-sum tests, reported as raw p-values and Benjamini-Hochberg adjusted q-values. Analyses used R and Python. Results 72 patients with MM were included. 40/72 (56%) previously underwent autologous hematopoietic cell transplantation (AHCT). 129 stool samples from 72 patients were profiled and classified as follows: baseline (N=54), on-len control (N=58), and on-len diarrhea (N=17). A GEE model (adjusted for AHCT, sex, and antibiotic exposure) revealed significantly lower alpha-diversity in on-len diarrhea samples compared to both baseline (p<0.001) and on-len control (p=0.004). Beta-diversity was significantly shifted in the on-len diarrhea group from both the baseline and on-len control groups (F=3.9, p=0.001). In a FLORAL GEE model comparing baseline and on-len diarrhea groups, Faecalibacterium and Romboutsia genera were depleted in the on-len diarrhea group. Metabolomic profiling of BAs was performed in 103/129 samples. Primary BAs, which promote BA diarrhea, were significantly enriched in on-len diarrhea samples compared to baseline, including cholate (p=0.002) and chenodeoxycholate (p=0.010). Primary BAs are metabolized into secondary BAs by microbial enzymes; secondary BA levels were similar between baseline, on-len control and on-len diarrhea groups, including deoxycholate (overall p=0.679) and lithocholate (overall p=0.250). Despite the higher primary BA load, the predicted abundance of bile salt hydrolase (BSH), which mediates the first microbial step of BA metabolism, was significantly lower in the on-len diarrhea group compared to baseline (p=0.029) and on-len control groups (p=0.030). Predicted abundance of bai operon genes, which mediate downstream processing of secondary BAs, was similar between the three groups (overall p=0.890). Analysis of dietary macronutrient density from 39/72 patients with baseline data revealed those who developed diarrhea had a trend toward higher total fat intake (p=0.059). In an analysis of nutrient subclasses, patients who did not develop diarrhea had trends toward higher intake of soluble fiber (p=0.011; q=0.085) and insoluble fiber (p=0.067; q=0.178). Conclusion Our study provides the first evidence of gut microbiota dysbiosis in patients with LRD. We reveal primary BA enrichment in patients with LRD, which correlated with disrupted microbial processing capacity. These data suggest that beyond bile acid sequestration, strategies to improve gut microbial diversity and functional capacity may warrant further study for mitigation of LRD.

Article Details

Journal Blood
Volume / Issue Vol. 146, Issue Supplement 1
Published November 03, 2025
Pages 2233-2233
ISSN 0006-4971
Publisher Elsevier BV

Journal Info

Blood

Elsevier BV

ISSN: 0006-4971 Health Sciences

Authors (28)

K

Kevin Miller

1Memorial Sloan Kettering Cancer Center, Myeloma Service, Department of Medicine, New York, United States

T

Teng Fei

College of Life and Health Sciences, Northeastern University

R

Ruben Ramos

2Memorial Sloan Kettering Cancer Center, New York, United States

A

Ana Catarina Gradissimo De Oliveira

1Memorial Sloan Kettering Cancer Center, Pediatrics, New York, United States

J

Jennifer Haber

1Memorial Sloan Kettering Cancer Center, Pediatrics, New York, United States

M

Minsu Jaun

2Memorial Sloan Kettering Cancer Center, New York, United States

F

Francesca Castro

1Memorial Sloan Kettering Cancer Center, Myeloma and Cellular Therapy Services, New York, United States

A

Andriy Derkach

I

Issam Hamadeh

6Memorial Sloan Kettering Cancer Center, Department of Pharmacy, New York, United States

K

Kylee Maclachlan

2Myeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY

M

Malin Hultcrantz

1Memorial Sloan Kettering Cancer Center, Myeloma Service, Department of Medicine, New York, United States

H

Hani Hassoun

1Memorial Sloan Kettering Cancer Center, Myeloma Service, Department of Medicine, New York, United States

S

Sham Mailankody

Cellular Therapy Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York

S

Sridevi Rajeeve

1Memorial Sloan Kettering Cancer Center, Myeloma Service, Department of Medicine, New York, United States

F

Francesco Maura

Memorial Sloan Kettering Cancer Center, New York

M

Maximillian Merz

5Memorial Sloan Kettering Cancer Center, New York, United States

H

Hamza Hashmi

Memorial Sloan Kettering Cancer Center, New York

R

Ross Firestone

1Memorial Sloan Kettering Cancer Center, Myeloma Service, Department of Medicine, New York, United States

E

Eric Jurgens

1Memorial Sloan Kettering Cancer Center, Myeloma Service, Department of Medicine, New York, United States

G

Gunjan Shah

2Memorial Sloan Kettering Cancer Center, Cellular Therapy Service, Department of Medicine, New York, United States

M

Michael Scordo

Cellular Therapy Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York

H

Heather Landau

Adult Bone Marrow Transplantation Service Memorial Sloan Kettering Cancer Center New York New York USA

J

Jonathan Peled

1Memorial Sloan Kettering Cancer Center, Pediatrics, New York, United States

S

Sergio Giralt

1Adult Bone Marrow Transplantation Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY

N

Neha Korde

1Memorial Sloan Kettering Cancer Center, Myeloma Service, Department of Medicine, New York, United States

S

Saad Usmani

8Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY

U

Urvi Shah

1Memorial Sloan Kettering Cancer Center, Myeloma Service, Division of Hematologic Malignancies, Department of Medicine, New York, United States

A

Alexander Lesokhin

1Memorial Sloan Kettering Cancer Center, Myeloma Service, Department of Medicine, New York, United States